ANPEP and acute myeloid leukemia: Considering the risk that mAbs may induce a mechanism-dependent toxicity that can add to therapeutic activity as exemplified by the use of gemtuzumab ozogamicin in AML [21], we therefore investigated the possibility to induce the death of AML cells with the CNGRC-GG-D(KLAKLAK)2 peptide by targeting leukemic CD13.